Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315992ADJUVANT EFFECT OF THE TLR1/2 AGONIST DIPROVOCIM SYNERGIZES WITH CHECKPOINT-INHIBITING ANTIBODIES TO ELIMINATE DISEASE
US 14.10.2021
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No 17265333 Applicant The Board of Regents of the University of Texas System Inventor Bruce Beutler

A potent human and mouse Toll-like receptor (TLR)1/TLR2 agonist was identified and optimized, Diprovocim, which exhibited an EC50 of 110 pM in human THP-1 cells and 1.3 nM in primary mouse peritoneal macrophages. In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses, and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term anti-tumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. Diprovocim induced greater frequencies of tumor infiltrating leukocytes than alum, of which CD8 T cells were necessary for the antitumor effect of immunization plus anti-PD-L1 treatment.

2.20210315989METHODS TO PREPARE NASOPHARYNGEAL AND ORAL MATERIAL FOR ORAL INOCULATION OF COVID-19
US 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17223920 Applicant Steven Mark Hayden Inventor Steven Mark Hayden

The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.

3.WO/2021/204204ANTIGEN GENE TRANSFECTION CELL VACCINE AND RELATED IMMUNE CELL
WO 14.10.2021
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/CN2021/085973 Applicant CHINEO MEDICAL TECHNOLOGY CO., LTD. Inventor GU, Weiyue
Provided are a cell vaccine for an infection by a pathogenic micro-organism and an illness related to the infection, said vaccine can be prepared by means of in vitro transfection of autologous or allogeneic antigen-presenting cells with a pathogenic micro-organism antigen, and as such the antigen-presenting cells loaded with the pathogenic micro-organism antigen serve as a prophylactic or therapeutic vaccine. Further provided are an immune cell, comprising a T cell or an NK cell, which can be activated by the antigen-loaded vaccine of the present invention, or can be directly activated by a pathogenic micro-organism. Further provided is a composition simultaneously including the cell vaccine and immune cells, said composition being used for preventing or treating an infection caused by the pathogenic micro-organism and an illness related thereto.
4.WO/2021/207303IMMUNE STIMULATION AGAINST CORONAVIRUS INFECTIONS
WO 14.10.2021
Int.Class A61K 31/739
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
739Lipopolysaccharides
Appl.No PCT/US2021/026103 Applicant ALSATECH, INC. Inventor NICOLAU, Claude
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of infections that are caused by or associated with coronaviruses (e.g., SARS-CoV-2). In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in a patient, which is capable of preventing or alleviating coronavirus infections, or symptoms associated with coronavirus infections, including the novel SARS-CoV-2 infection, COVID-19.
5.WO/2021/207348METHOD OF TREATING AND PREVENTING OCULAR DISEASE WITH HSV-2 DELTA GD
WO 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/026158 Applicant ALBERT EINSTEIN COLLEGE OF MEDICINE Inventor HEROLD, Betsy C.
Methods of treating or preventing ocular disease caused by herpes simplex virus-1 infection are provided, and comprise administering to a subject an effective amount of a herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome to treat or prevent ocular disease in the subject, wherein the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D by propagating the HSV-2 in a complementing cell expressing the HSV-1 glycoprotein D.
6.20210317454USE OF A TLR9 AGONIST IN METHODS FOR TREATING COVID-19
US 14.10.2021
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
Appl.No 17226866 Applicant Idera Pharmaceuticals, Inc. Inventor Srinivas CHUNDURU

The present invention is directed to use of tilsotolimod in the treatment of coronavirus infection, for example, SARS-CoV2, and COVID-19.

7.WO/2021/207306RECOMBINANT BACTERIA FOR USE AS A VACCINE TO PREVENT COVID19 INFECTION
WO 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/026106 Applicant SYNLOGIC OPERATING COMPANY, INC. Inventor GAO, Jian-Rong
Modified microorganisms, pharmaceutical compositions thereof, and methods of preventing and treating the coronavirus disease 2019 (COVID-19) are disclosed.
8.WO/2021/207486TREATMENTS
WO 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/026367 Applicant AERIE PHARMACEUTICALS, INC. Inventor DELONG, Mitchell, A.
Described herein are compounds, combinations of compounds, compositions, formulations, and methods of treating viruses, viral load, and manifestations of viral infections.
9.WO/2021/205446PICKERING EMULSION-BASED VACCINES
WO 14.10.2021
Int.Class A61K 9/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
Appl.No PCT/IL2021/050390 Applicant THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) Inventor MECHREZ, Guy
A particle comprising a shell comprising an immunogenic nanoparticle bound to at least one epitope and in contact with the shell, is provided. An emulsion comprising a plurality of said particles is also provided, such as for vaccinating a subject in need thereof.
10.WO/2021/205027INDIVIDUALIZED THERAPEUTIC ANTICANCER VACCINE
WO 14.10.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/EP2021/059353 Applicant VACCIBODY AS Inventor FREDRIKSEN, Agnete, Brunsvik
The present invention relates to an individualized therapeutic anticancer vaccine, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine.